Indegene P/E Ratio
Indegene (INDGN) P/E ratio is 30.51 (High), EPS (TTM) ₹16.72, current price ₹492.65 on NSE vs historical average P/E of 33.87 — Very High - High growth expectations or significantly overvalued. See INDGN P/B ratio history to compare market price against book value per share.
Current Valuation Metrics
Valuation Signal
Sector Context
Earnings Breakdown (TTM)
INDGN P/E Ratio — Valuation Signal & Historical Context
Indegene P/E 30.51 vs historical average 33.87, range 33.12–34.62 — signal: Overvalued. Read INDGN dividend yield for the complete payout history and dividend yield track record.
- Stock appears overvalued with PE of 30.51, suggesting caution for new investments
- Trading at discount to sector average PE of 55.76
Indegene P/E Ratio Historical Trend
INDGN annual price-to-earnings ratio — 2 years, EPS and year-end price. Current P/E 30.51 vs historical average 33.87. For live price, revenue and the complete fundamental profile, see Indegene share price today.
INDGN Historical P/E Ratio — EPS, Year-End Price & Valuation
Indegene annual P/E ratio, EPS (₹), year-end price and valuation category on NSE.
| Year | P/E Ratio | EPS (₹) | Year-end Price (₹) | Exchange | Valuation |
|---|---|---|---|---|---|
| 2025 | 33.12 | 18.32 | ₹606.80 | NSE | High |
| 2024 | 34.62 | 16.49 | ₹570.90 | NSE | High |
INDGN vs Healthcare Peers — P/E Ratio Comparison
Indegene P/E 30.51 vs Healthcare average 55.76, median 31.44 — range 2.86–916.67.
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.61 | ₹64 | Low |
| Sunrest Lifescience | SUNREST | 3.76 | ₹30 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.76 | ₹7,399 | Low |
| Shelter Pharma | SHELTER | 5.23 | ₹47 | Low |
| Dipna Pharmachem | DPL | 5.39 | ₹14 | Low |
| JFL Life Sciences | JFLLIFE | 5.41 | ₹68 | Low |
| Amwill Health Care | AMWILL | 7.26 | ₹83 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹84 | Low |
| Galaxy Medicare | GML | 7.8 | ₹27 | Low |